USA: Trump verkündet weitere Abkommen zur Senkung von Medikamentenpreisen
Das Weiße Haus spricht von „enormen Rabatten“, die die Pharmakonzerne US-Kosten geben wollen. Verbraucherschutzorganisationen äußern sich jedoch skeptisch.
U.S. President Donald Trump announced new agreements on Monday to lower medication prices with several pharmaceutical companies. Among the corporations involved were Australian CSL, Indian Sun Pharmaceutical, and Belgian UCB, as reported by Trump at a White House meeting. The companies pledged to offer generic drugs for the Medicaid health program at preferential prices, which Trump claimed would be a "massive discount that could significantly reduce medical care costs."
However, it remains unclear how many medications the agreements cover and the extent of savings for the state or patients. The White House did not release detailed information. Critics, such as consumer advocacy group Public Citizen, expressed skepticism, suggesting the new agreements were a diversion from the government's failed plan to bring U.S. medication prices down to the level of other wealthy nations.
Medicaid already receives substantial discounts from manufacturers under current law. The background is that U.S. consumers pay considerably more for prescription drugs than in most other industrialized nations. The government had already signed similar deals with 17 of the world's largest pharmaceutical firms last year, including Pfizer, Eli Lilly, and Novo Nordisk.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
